• LLY
• NVO

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk remains optimistic about CagriSema, a new obesity drug, despite disappointing trial results. Plans for further trials and regulatory submission are in place to enhance its market potential.

• BIIB
• JNJ
• LLY
• NBI
• NVO
• PFE
• US500

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

The biopharmaceutical industry seeks to rebound in 2025, navigating uncertainty from regulatory changes and potential impacts from President Trump's administration on drug pricing and vaccine policies.

• LLY
• NVO

Retail investors buy Novo dip after disappointing weight-loss drug data

Retail investor interest in Novo Nordisk surged after underwhelming obesity drug data, leading to a significant dip in share price while comparisons with Eli Lilly highlighted rising competition in weight-loss treatments.

• 1YMH25
• AVGO
• DJI
• ESH25
• IXIC
• LLY
• META
• NQH25
• NVDA
• QCOM
• US500

US stock futures steady after tech rally pushes Wall street higher

U.S. stock futures remain steady before Christmas as technology stocks rally. Wall Street rebounds from recent losses, and chip stocks, including Broadcom and Qualcomm, see significant gains.

• LLY
• REGN

US FDA revokes authorization for four COVID antibody drugs

The FDA revoked emergency use authorization for four antibody drugs due to expired shelf life and lack of efficacy against circulating variants, signaling the end of their U.S. availability.

• LLY
• NVO

Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea

The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea in obese adults, marking a significant advancement in addressing this widespread disorder and expanding market potential.

• BRKa
• COIN
• FDX
• LLY
• NKE
• NVO
• OXY
• TSLA

FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall

• AMGN
• GPCR
• LLY
• NVO
• VKTX

Viking Therapeutics stock surges 12% amid Novo Nordisk trial woes

• LLY
• NOVOb

Novo Nordisk sinks on latest data, Lilly gains

Novo Nordisk shares fell nearly 28% after CagriSema's trial results showed lower than expected weight loss, while Eli Lilly's shares rose 10% amidst the news.

• LLY
• NVO

Novo slumps, Lilly gains on trial data results

Novo Nordisk's shares fell 19% after phase 3 trial results for CagriSema, an obesity drug, disappointed. Eli Lilly's stock rose amid growing confidence in its obesity treatments.